CEOs, Senior Executives Highlight Strategies, M&A, and Expansions at DCAT Week

Chief executive officers and senior executives from DCAT member companies provided key updates on strategy, mergers and acquisitions, and expansions at the DCAT Member Company Announcement Forum held during DCAT Week in mid-March.

The executives highlighted key company activity impacting the pharmaceutical manufacturing value chain. SCHOTT, Catalent, Thermo Fisher Scientific, Cambrex, Lonza, BSP Pharmaceuticals, Servier CDMO, Selkirk Pharma, Seqens, Cerbios-Pharma, and ACG were among the companies taking the podium to provide their latest developments (see announcements below).

SCHOTT Plans $1-Billion Expansion in Pharma Packaging

Catalent Investing $214 Million to Expand Biologics Capabilities; Invests in Oral Delivery Capabilities

Thermo Fisher Scientific Investing $150 Million in Sterile Injectables Development and Manufacturing

Cambrex Updates Integration of Halo Pharma and Avista Pharma; Expands Small-Molecule API Mfg

Lonza Updates $100-Million Expansion for High-Potency APIs and Small-Molecule Mfg

BSP To Add High-Containment Capacity for Conjugation and Injectable Drug Products

Servier CDMO Invests $55 Million for Bioproduction and $7 Million for Industrial Prep Chromatography

New CDMO Selkirk Pharma Investing $30 Million in Aseptic Fill–Finish Facility

Seqens Investing $30 Million to Expand High-Potency Manufacturing

Cerbios-Pharma Investing in New High-Potency API Production Line and Conjugation Suite

ACG Expands Capsule Production in Brazil, India, and Croatia

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Feature Articles

Will New Oral GLP-1 Agonists Be the Next Market Shaker?

By
The blockbuster success of Novo Nordisk’s Ozempic/Wegovy and Lilly’s Mounjaro/Zepbound, all injectables, have put GLP-1/GIP agonists on the map, but will new oral drugs be a game-changer?

The Push To Onshore US Pharma Manufacturing: What’s on the Table?

By
Congress is moving forward with proposed legislation to increase both new and reshored pharma manufacturing in the US. What measures are being considered, and where do they stand?

On the Rise: CDMO/CMO Expansions for Injectables

By
Strong growth is projected for the injectables drugs market, and CDMOs/CMOS are expanding sterile manufacturing & fill–finish capacity. Which companies are expanding and who is leading the charge?

Pharma Industry-Specific Tariffs: Industry Weighs In

By
The industry has weighed in on the US government’s potential plan to impose tariffs specific to the pharmaceutical industry. Where does the initiative stand, and what is the industry saying?